

California State Board of Pharmacy

2720 Gateway Oaks Drive, Suite 100

Sacramento, CA 95833

Phone: (916) 518-3100 Fax: (916) 574-8618

www.pharmacy.ca.gov

Business, Consumer Services and Housing Agency Department of Consumer Affairs Gavin Newsom, Governor



Notice of Meeting and Agenda Teleconference Public Board Meeting

Date & Time: September 12, 2023, 9:00 a.m.

Place: Department of Consumer Affairs

1625 N. Market Blvd, First Floor Hearing Room

Sacramento, CA 95834

The Board is providing members of the public with different options to observe or participate in the meeting.

FOR OBSERVATION AND PUBLIC COMMENT IN PERSON:

Department of Consumer Affairs 1625 N. Market Blvd, First Floor Hearing Room Sacramento, CA 95834

Hotel Dena, Pasadena Los Angeles, A Tribute Portfolio Hotel Magnolia Room 303 Cordova Street Pasadena, CA 91101

California Contractors State Licensing Board 9246 Lightwave Ave., Suite 130 San Diego, CA 92123

FOR PUBLIC PARTICIPATION AND COMMENT FROM A REMOTE LOCATION, PLEASE LOG ON

TO WEBEX: To access the WebEx event, attendees will need to click the following link and enter a first name, last name, email, and the event password listed below:

WebEx for September 12, 2023:

https://dca-meetings.webex.com/dca-meetings/j.php?MTID=mc105b0643bf7fc31356802c85e8440fb

<u>If joining using the link above</u>
Webinar number: 2481 800 0526
Webinar password: CSBP09122023

<u>If joining by phone</u>

+1-415-655-0001 US Toll

Access code: 248 180 00526

Passcode: 27270912

Members of the public participating via WebEx will be able to hear the meeting and provide public comment but may not be able to observe the meeting. The preferred audio connection is via phone bridge. The phone number and access code will be provided as part of your connection to the meeting.

Members of the public may but are not obligated to provide their names or personal information as a condition of observing or participating in the meeting. When signing into the WebEx platform, participants may be asked for their name and email address. Participants who choose not to provide their names will need to provide a unique identifier such as their initials or another alternative, so that the meeting moderator can identify individuals who wish to make public comment; participants who choose not to provide their email address may utilize a fictitious email address in the following sample format: XXXXX@mailinator.com.

FOR OBSERVATION ONLY:

Livestream: The Board plans to webcast this meeting on the Department of Consumer Affairs' website at https://thedcapage.blog/webcasts. Livestream will be available at the earliest at 9:00 a.m. on September 12, 2023. Using the Livestream link will allow only for observation with closed captioning. Livestream availability cannot, however, be guaranteed due to resource limitations or technical difficulties. The meeting will not be cancelled if webcast is unavailable. If you wish to participate, please plan to participate via the WebEx option listed above.

IMPORTANT NOTICES TO THE PUBLIC: The Board will hold a meeting in person that also includes participation by the public either in person at the public location(s) identified on the first page of this agenda or via WebEx – access information is provided above. The meeting is open to the public and is accessible to the physically disabled. A person who needs a disability-related accommodation or modification in order to participate in the meeting may make a request by contacting Debbie Damoth at (916) 518-3090, emailing Debbie.Damoth@dca.ca.gov, or sending a written request to the Board of Pharmacy, 2720 Gateway Oaks Drive, Suite 100, Sacramento CA 95833. Providing your request at least five business days before the meeting will help to ensure availability of the requested accommodation.

The time and order of agenda items are subject to change at the discretion of the Board President. In the event a quorum of the Board is unable to attend the meeting, or the Board is unable to maintain a quorum once the meeting is called to order, the members present may, at the Board President's discretion, continue to discuss items from the agenda, and/or continue pursuant to Business and Professions Code section 4309(c), and make recommendations to the full Board at a future meeting.

Government Code section 11125.7 provides the opportunity for the public to address each agenda item during discussion or consideration by the Board or prior to the Board taking any action on said item. Members of the public will be provided appropriate opportunities to comment on any issues before the Board, but the Board President may, at their discretion, apportion available time among those who wish to speak. If public comment

is not specifically requested, members of the public should feel free to request an opportunity to comment. Individuals may appear before the Board to discuss items not on the agenda; however, the Board can neither discuss nor take official action on these items at the time of the same meeting (Government Code sections 11125, 11125.7(a)).

<u>Agenda</u>

Discussion and action make be taken on any agenda item.

September 12, 2023

Call to Order 9:00 a.m.

- I. Call to Order, Establishment of Quorum, and General Announcements
- II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings

 Note: The Board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)]
- III. <u>Recognition and Celebration of Pharmacists Licensed in California for 40 years and other</u> Recognitions
- IV. Approval of Board and Ad Hoc Committee Meeting Minutes
 - a. April 19-20, 2023, Board Meeting
 - b. May 3, 2023, Standard of Care Ad Hoc Committee Meeting
 - c. May 17, 2023, Board Meeting
 - d. June 7, 2023, Medication Error Reduction and Workforce Ad Hoc Committee Meeting
 - e. June 21, 2023, Board Meeting
- V. Discussion and Consideration on the Board's Strategic Plan
- VI. <u>Discussion and Consideration of Draft Notice to Consumers Poster, Consistent with the Proposed Changes to Title 16, California Code of Regulations section 1707.6</u>
- VII. <u>Discussion and Consideration of Draft Proposed Policy Statement Related to Implementation of USP General Chapters 795 Pharmaceutical Compounding Nonsterile Preparations; 797 Pharmaceutical Compounding Sterile Preparations; 800 Hazardous Drugs Handling in Healthcare Settings; and 825 Radiopharmaceuticals Preparation, Compounding, Dispensing, and Repackaging</u>

VIII. <u>Discussion and Consideration of Recommendations to Delete Previously Approved New Regulation Text from Proposed 16 CCR sections 1737.7, subdivision (e) Related to the use of Respirators and 1737.18 Related to Medical Surveillance</u>

IX. <u>Petitions for Reinstatement of Licensure, Early Termination of Probation, or Other Modification of Penalty</u>

- a. Nimesh M. Patel, RPH 52508
- b. Fred Ibarra, TCH 40995
- c. The Diennet Pharmacy, PHY 44310
- d. Afifi G. Armanyous, RPH 45321

X. Closed Session Matters

- a. Pursuant to Government Code Section 11126(c)(3), the Board will Convene in Closed Session to Deliberate on Disciplinary Matters, Including Proposed Decisions, Stipulated Settlements, Default Decisions, Petitions for Reinstatement or Modification of Penalty, and Any Other Disciplinary Matters
- b. Pursuant to Government Code Section 11126(c)(1), the Board will Convene in Closed Session to Consider the Preparation, Approval, Grading, or Administration of One or More Licensing Examination(s)
- c. Pursuant to Government Code Section 11126(e)(1), the Board Will Convene in Closed Session to Confer with its Legal Counsel Regarding Pending Litigation
 - Absolute Pharmacy LLC dba Absolute Pharmacy LLC; Andreas Dieter Dettlaff v. California Board of Pharmacy, et al., Los Angeles Superior Court, (Case No. 22STCP04253).

XI. Reconvene in Open Session, to adjourn for the Day

Due to technological limitations, adjournment for the day may not be broadcast. Adjournment will immediately follow closed session, and there will be no other items of business discussed.

XII. Adjournment

Upon conclusion of business